---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-097575"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:56:06.921324+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Korro Bio raises $85M in PIPE led by Venrock; cash runway into H2 2028

## Summary
- Gross proceeds ~$85M from 4,501,928 shares at $11.11 and 3,148,836 pre-funded warrants at $11.109.
- Preliminary cash, equivalents, marketable securities of $85.2M as of Dec 31, 2025; runway through H2 2028.
- Proceeds fund clinical milestones: KRRO-121 for urea cycle disorders and GalNAc-conjugated AATD program.
- Closing expected March 10, 2026; placement agents include Citigroup, Cantor, Oppenheimer, William Blair.

## SEC filing metadata
- accession: 0001193125-26-097575
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312526097575/0001193125-26-097575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312526097575/krro-20260309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-097575
- JSON: https://secwatch.observer/filing/0001193125-26-097575.json
- Plain text: https://secwatch.observer/filing/0001193125-26-097575.txt

## Key facts
- Material Agreements
  Korro Bio, Inc. entered into subscription agreement with a number of institutional accredited investors valued at approximately $85.0 million (effective 2026-03-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a number of institutional accredited investors
  - Value: approximately $85.0 million
  - Effective: 2026-03-09
  source text: Korro Bio, Inc., or Korro, entered into a subscription agreement with a number of institutional accredited investors pursuant to which it agreed to sell and issue in a private placement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312526097575/0001193125-26-097575-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.